“The recognition from the expert committee that awarded us the Lider Invest award for the best large-scale production investment is yet another proof that we made the right choice by launching the Pharma Valley project, whose first and most challenging phase was completed in mid-2015. This is the result of a group effort of all our former and current employees, who contributed their efforts, work and innovations to the development of JGL,” said Mate Poropat, MPharm, JGL’s executive director for pharmaceutical and technical operations, during his acceptance speech for the Lider Invest award for the best large-scale production investment.
The two key goals of the project – securing the prerequisites and capacities in development, production and storage for the realisation of the company’s long-term growth plans, and bringing together all production and technological locations in one place – have been fully realised. Up to this point, HRK 358 million has been invested in production, storage and other facilities at the Svilno 2 site. The investment is a real milestone in the development of this company that has been around for a quarter of a century, as well as a stepping stone for its future. JGL’s facilities export products to all parts of the world, and their quality is crucial for strengthening JGL’s position on existing markets, and for opening new ones. “Finding and maintaining market positions in an extremely competitive business environment would be impossible without investing in state-of-the-art technology, which is the backbone of the entire Svilno investment.
This is an integrated approach that combines the best practices in the management of production processes, the latest technologies in pharmaceutical production, and the application of the highest environmental standards. We believe this is the only right approach for companies that want to establish a long-term sustainable business model,” says Poropat. JGL continues to position itself on the global market, and aims to become specialized in the development and production of value-added sterile products in ophthalmology and otorhinolaryngology in accordance with its vision.
By developing a wide range of Aqua Maris products, this domestic company has established itself as a global leader in using sea water for health purposes. In addition to a strong presence in the Russian Federation and South East Europe, this year has been the first in which JGL exported its products to Spain. In addition, in cooperation with its renowned partners, the company entered the markets in the ASEAN region – namely, Thailand, Vietnam, Singapore and Malaysia – and exported its first products from the Aqua Maris range to this area.
The Lider Invest project was launched by the Lider Media publishing house.